International Journal of Management and Organizational Research

Supply Chain Resilience in the Pharmaceutical Industry: Strategies for Mitigating Disruptions and Ensuring Availability

Isaac Awulu¹, Valentina Ochuko Obukadata², Imoiboho Williams³

1. ¹
2. ²
3. ³

Abstract

The pharmaceutical supply chain occupies an unusual position among global supply networks. It is simultaneously one of the most heavily regulated, most geographically concentrated, and most consequential systems in modern commerce, since its failure modes are measured not in lost revenue but in delayed chemotherapy, rationed diagnostic imaging, and untreated childhood infections. The period between 2020 and 2022 subjected this system to a sequence of stress tests: a global pandemic, export restrictions on active pharmaceutical ingredients, a two-month lockdown of Shanghai, a war in Europe with attendant energy and logistics shocks, and an unusually severe respiratory infection season that collided with an already thin manufacturing base for paediatric antibiotics. This paper examines why the pharmaceutical supply chain proved fragile under these conditions and what strategies demonstrably improved its performance. It adopts an integrative review methodology combined with secondary data analysis and a comparative examination of three 2022 disruption episodes: the global iodinated contrast media shortage triggered by the Shanghai lockdown, the shortage of paediatric amoxicillin formulations during the winter respiratory season, and the stimulant shortage arising from the interaction of manufacturing delays with regulatory production quotas. A fourth case, the distribution of COVID-19 vaccines, is treated as a partial counterexample in which deliberate redundancy and public investment produced a comparatively resilient outcome. The analysis yields three central findings. First, the dominant vulnerability in pharmaceutical supply is not geographic distance but node concentration. Single site manufacture of high volume, low margin products creates conditions in which one localised event propagates globally within weeks. Second, resilience capabilities are asymmetrically distributed: large originator firms handling patented biologics possess visibility and buffering capacity that generic manufacturers of sterile injectables and oral solids largely do not, and it is precisely the latter category where shortages concentrate. Third, resilience in this sector cannot be built by firms acting alone, because the economics of generic medicines punish the very investments that resilience requires. The paper proposes a four-layer resilience framework organised around visibility, buffering, flexibility, and collaborative governance, supported by three enablers: digital infrastructure, regulatory agility, and procurement reform. It concludes with differentiated recommendations for manufacturers, health systems, regulators, and policymakers in low- and middle-income countries, and identifies a research agenda centred on the measurement of resilience and the design of procurement mechanisms that price reliability rather than unit cost alone.  

Keywords: supply chain resiliencepharmaceutical supply chaindrug shortagesmedicine availabilitydisruption managementactive pharmaceutical ingredientshealth system preparedness

How to cite

Licensed under CC BY 4.0.